

Kyung Hee Jung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3013398/publications.pdf>

Version: 2024-02-01

41
papers

980
citations

516710

16
h-index

454955

30
g-index

42
all docs

42
docs citations

42
times ranked

1819
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Bone Marrow-Derived Clonal Mesenchymal Stem Cells Inhibit Inflammation and Reduce Acute Pancreatitis in Rats. <i>Gastroenterology</i> , 2011, 140, 998-1008.e4.	1.3	159
2	20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. <i>Oncotarget</i> , 2014, 5, 4438-4451.	1.8	92
3	Progress in cancer therapy targeting c-Met signaling pathway. <i>Archives of Pharmacal Research</i> , 2012, 35, 595-604.	6.3	76
4	Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. <i>Cancer Letters</i> , 2017, 396, 155-166.	7.2	55
5	Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. <i>Cancer Letters</i> , 2017, 403, 339-353.	7.2	41
6	An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 155.	3.7	39
7	KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. <i>Cancer Letters</i> , 2018, 438, 174-186.	7.2	38
8	Systematic assessment of cervical cancer initiation and progression uncovers genetic panels for deep learning-based early diagnosis and proposes novel diagnostic and prognostic biomarkers. <i>Oncotarget</i> , 2017, 8, 109436-109456.	1.8	37
9	HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 78029-78047.	1.8	35
10	HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. <i>Cancer Letters</i> , 2012, 316, 187-195.	7.2	34
11	Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells. <i>Biomolecules and Therapeutics</i> , 2020, 28, 527-536.	2.4	30
12	Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 112893-112906.	1.8	29
13	<i>Artemisia Capillaris</i> leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 147.	3.7	25
14	An ethyl acetate fraction of <i>Artemisia capillaris</i> (ACE63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma. <i>Phytotherapy Research</i> , 2018, 32, 2034-2046.	5.8	21
15	Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer. <i>Oncotarget</i> , 2014, 5, 9150-9168.	1.8	21
16	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9205-9221.	6.4	18
17	ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis. <i>Cancer Letters</i> , 2021, 519, 185-198.	7.2	17
18	HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer. <i>Cancer Letters</i> , 2019, 444, 94-104.	7.2	16

#	ARTICLE	IF	CITATIONS
19	Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. <i>Cancer Letters</i> , 2013, 328, 176-187.	7.2	15
20	<i>Artemisia capillaris</i> extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 134-141.	5.6	15
21	ANGPTL 4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a. <i>EMBO Molecular Medicine</i> , 2020, 12, e11222.	6.9	15
22	HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. <i>Oncotarget</i> , 2015, 6, 1507-1518.	1.8	14
23	A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. <i>Journal of the National Cancer Institute</i> , 2022, 114, 228-234.	6.3	12
24	HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. <i>Cancer Letters</i> , 2014, 348, 50-60.	7.2	11
25	Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. <i>Cancer Letters</i> , 2014, 353, 68-77.	7.2	11
26	Apoptotic Effects of <i>Xanthium strumarium</i> via PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-13.	1.2	11
27	PBT-6, a Novel PI3KC2 β Inhibitor in Rheumatoid Arthritis. <i>Biomolecules and Therapeutics</i> , 2020, 28, 172-183.	2.4	11
28	A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques. <i>International Journal of Oncology</i> , 2013, 42, 2001-2008.	3.3	10
29	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. <i>International Journal of Oncology</i> , 2014, 45, 311-321.	3.3	10
30	Aminoacyl-tRNA synthetase interacting multi-functional protein 1 attenuates liver fibrosis by inhibiting TGF β 2 signaling. <i>International Journal of Oncology</i> , 2016, 48, 747-755.	3.3	10
31	Comparative analysis of mesenchymal stem cells cultivated in serum free media. <i>Scientific Reports</i> , 2022, 12, .	3.3	8
32	CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. <i>International Journal of Oncology</i> , 2015, 47, 253-261.	3.3	7
33	Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. <i>Cancer Letters</i> , 2021, 507, 97-111.	7.2	7
34	A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. <i>Cancer Letters</i> , 2018, 426, 25-36.	7.2	6
35	MEK blockade overcomes the limited activity of palbociclib in head and neck cancer. <i>Translational Oncology</i> , 2020, 13, 100833.	3.7	6
36	HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy. <i>Oncotarget</i> , 2014, 5, 10180-10197.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Artemisiae Iwayomogii Herba Inhibits Growth, Motility, and the PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma Cells. <i>Planta Medica</i> , 2020, 86, 717-727.	1.3	4
38	Optimization and biological evaluation of aminopyrimidine-based I β B kinase \hat{I}^2 inhibitors with potent anti-inflammatory effects. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 544-556.	5.5	3
39	Combination Therapy of the Active KRAS-Targeting Antibody in Ras37 and a PI3K Inhibitor in Pancreatic Cancer. <i>Biomolecules and Therapeutics</i> , 2022, 30, 274-283.	2.4	3
40	Reply. <i>Gastroenterology</i> , 2013, 145, 257-258.	1.3	1
41	SB365 induces apoptosis and suppresses proliferation of glioblastoma cells. <i>Indian Journal of Pharmacology</i> , 2020, 52, 102.	0.7	1